Nonoperating Income (Expense) of Werewolf Therapeutics, Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary: Werewolf Therapeutics, Inc. quarterly and annual Nonoperating Income (Expense) in USD history and change rate from 31 Mar 2020 to 30 Sep 2025.
Werewolf Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending 30 Sep 2025 was $644,000, a 243% decline year-over-year.
Werewolf Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending 30 Sep 2025 was $1,234,000, a 130% decline year-over-year.
Werewolf Therapeutics, Inc. annual Nonoperating Income (Expense) for 2024 was $3,079,000, a 1.8% decline from 2023.
Werewolf Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $3,135,000, a 40% increase from 2022.
Werewolf Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was $2,246,000, a 2060% increase from 2021.
Source SEC data: View on sec.gov

Nonoperating Income (Expense), Trailing 12 Months (USD)

Nonoperating Income (Expense), Quarterly (USD)

Nonoperating Income (Expense), YoY Quarterly Change (%)

Nonoperating Income (Expense), Annual (USD)

Nonoperating Income (Expense), YoY Annual Change (%)

Werewolf Therapeutics, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025	$1,234,000	$644,000	-$1,095,000	-243%	01 Jul 2025	30 Sep 2025	10-Q	04 Nov 2025	2025	Q3
Q2 2025	$139,000	$440,000	-$2,151,000	-126%	01 Apr 2025	30 Jun 2025	10-Q	14 Aug 2025	2025	Q2
Q1 2025	$2,012,000	$98,000	-$1,067,000	-110%	01 Jan 2025	31 Mar 2025	10-Q	08 May 2025	2025	Q1
Q4 2024	$3,079,000	$52,000	-$1,011,000	-105%	01 Oct 2024	31 Dec 2024	10-K	11 Mar 2025	2024	FY
Q3 2024	$4,090,000	$451,000	-$515,000	-53%	01 Jul 2024	30 Sep 2024	10-Q	04 Nov 2025	2025	Q3
Q2 2024	$4,605,000	$1,711,000	+$742,000	+77%	01 Apr 2024	30 Jun 2024	10-Q	14 Aug 2025	2025	Q2
Q1 2024	$3,863,000	$969,000	+$728,000	+302%	01 Jan 2024	31 Mar 2024	10-Q	08 May 2025	2025	Q1
Q4 2023	$3,135,000	$959,000	-$290,000	-23%	01 Oct 2023	31 Dec 2023	10-K	11 Mar 2025	2024	FY
Q3 2023	$3,425,000	$966,000	+$370,000	+62%	01 Jul 2023	30 Sep 2023	10-Q	07 Nov 2024	2024	Q3
Q2 2023	$3,055,000	$969,000	+$591,000	+156%	01 Apr 2023	30 Jun 2023	10-Q	08 Aug 2024	2024	Q2
Q1 2023	$2,464,000	$241,000	+$218,000	+948%	01 Jan 2023	31 Mar 2023	10-Q	03 May 2024	2024	Q1
Q4 2022	$2,246,000	$1,249,000	+$1,234,000	+8227%	01 Oct 2022	31 Dec 2022	10-K	07 Mar 2024	2023	FY
Q3 2022	$1,012,000	$596,000	+$559,000	+1511%	01 Jul 2022	30 Sep 2022	10-Q	14 Nov 2023	2023	Q3
Q2 2022	$453,000	$378,000	+$343,000	+980%	01 Apr 2022	30 Jun 2022	10-Q	10 Aug 2023	2023	Q2
Q1 2022	$110,000	$23,000	+$6,000	+35%	01 Jan 2022	31 Mar 2022	10-Q	11 May 2023	2023	Q1
Q4 2021	$104,000	$15,000	+$25,000		01 Oct 2021	31 Dec 2021	10-K	23 Mar 2023	2022	FY
Q3 2021	$79,000	$37,000	+$52,000		01 Jul 2021	30 Sep 2021	10-Q	10 Nov 2022	2022	Q3
Q2 2021	$27,000	$35,000	-$7,287,000	-100%	01 Apr 2021	30 Jun 2021	10-Q	11 Aug 2022	2022	Q2
Q1 2021	$7,314,000	$17,000	-$50,000	-75%	01 Jan 2021	31 Mar 2021	10-Q	10 May 2022	2022	Q1
Q4 2020	$7,364,000	$10,000			01 Oct 2020	31 Dec 2020	10-K	24 Mar 2022	2021	FY
Q3 2020		$15,000			01 Jul 2020	30 Sep 2020	10-Q	10 Nov 2021	2021	Q3
Q2 2020		$7,322,000			01 Apr 2020	30 Jun 2020	10-Q	12 Aug 2021	2021	Q2
Q1 2020		$67,000			01 Jan 2020	31 Mar 2020	10-Q	10 Jun 2021	2021	Q1

Werewolf Therapeutics, Inc. Annual Nonoperating Income (Expense) (USD)

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2024	$3,079,000	-$56,000	-1.8%	01 Jan 2024	31 Dec 2024	10-K	11 Mar 2025	2024	FY
2023	$3,135,000	+$889,000	+40%	01 Jan 2023	31 Dec 2023	10-K	11 Mar 2025	2024	FY
2022	$2,246,000	+$2,142,000	+2060%	01 Jan 2022	31 Dec 2022	10-K	07 Mar 2024	2023	FY
2021	$104,000	-$7,260,000	-99%	01 Jan 2021	31 Dec 2021	10-K	23 Mar 2023	2022	FY
2020	$7,364,000			01 Jan 2020	31 Dec 2020	10-K	24 Mar 2022	2021	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.